The outline of the current project is to establish a cohort of patients with treatment
refractory schizophrenia eligible for clozapine, to identify clinical and biological
characteristics of clozapine responding patients. Patients will be offered treatment with
clozapine according to national clinical guidelines. Before clozapine is initiated, patients
will be offered a thoroughly neurobiological examination, and re-examination will be carried
out after 12 weeks of treatment. The primary focus of the examinations will be immunological
markers and autoantibodies in the blood and cerebrospinal fluid, permeability of the
blood-brain barrier and magnetic resonance imaging of structural, neurochemical and
functional brain changes.
Phase:
Phase 4
Details
Lead Sponsor:
Mental Health Services in the Capital Region, Denmark